Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study

NCT ID
NCT07224607
Registry status
Recruiting
Study type
Interventional
Phase
Not applicable
Sponsor
Cedars-Sinai Medical Center
Conditions
Alzheimer's Disease

Overview

ClinicalTrials.gov lists this study as Recruiting.

Official title: A Longitudinal Study Investigating the Effects of Photobiomodulation (PBM) on Cognitive Function and Alzheimer's Disease (AD)-Related Biomarkers in Individuals With Mild Cognitive Impairment (MCI) or Dementia Due to AD

Enrollment: 45 participants (Estimated).

What is being studied

  • Intervention: Laser Therapy
  • Intervention: Low-Level Light Therapy
  • Device: Photobiomodulation
  • Intervention: Phototherapy
  • Intervention: Therapeutics

Who may be eligible

Ages
55 Years to 89 Years
Sex
All
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * Signed and dated informed consent form (either by subject or LAR) * Willingness and ability to comply with all study procedures * Age 55 to 89 years, inclusive * Clinical diagnosis of Mild Cognitive Impairment or mild dementia (CDR Global = 0-1; MoCA 16-25) due to probable Alzheimer's disease diagnosis * Ability to attend in-person sessions at Cedars-Sinai and adhere to weekly visits * Stable dose of Alzheimer's disease medications (e.g., donepezil, rivastigmine, memantine, galantamine) for at least 4 weeks prior to enrollment, if applicable Exclusion Criteria: * Presence of significant neurological conditions other than AD (e.g., epilepsy, Parkinson, etc.) * History of Seizures * If patient holds neuroimaging showing space-occupying lesions * If patient holds imaging with Fazekas greater than or equal to 3, more than 2 lacunar infarcts, and/or more than 5 microhemorrhages * Current pregnancy or lactation (although unlikely in this population) * Participation in another clinical trial or investigational drug within the past 30 days * Active use of illicit substances or non-prescribed psychoactive drugs within the past 30 days. * Severe dementia due to Alzheimer's disease or another etiology * Physical or mental impairment that prevents the participant from complying with the cognitive testing battery.

Study locations

1 study location is listed.

Recruiting site status is explicitly provided for 1 location; 1 is listed as Recruiting.

Countries: United States

  • California, United States: 1

Sample of listed locations

  • CSMC — Los Angeles, California, 90048, United States — Recruiting

Study details

Start date
September 1, 2026
Primary completion date
November 28, 2027
Completion date
March 30, 2028
First posted
November 4, 2025

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT07224607
Registry last updated
October 13, 2026
QualifiedStudies registry data refreshed
October 19, 2026
QualifiedStudies record fetched
October 19, 2026

View NCT07224607 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Alzheimers Disease studies | Clinical trial FAQ